Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will comprise the recent evidence concerning the effects of low perfusion pressure on glaucoma development and progression.
The Scientific Committee invites you to participate actively in this congress which will be an extraordinary occasion for the exchange of thoughts and experiences. We look forward to receiving abstracts for consideration and inclusion in the program as oral or poster presentations.
Management of the geographic atrophy seen in late-stage dry age-related macular degeneration (AMD) poses several challenges. Scientific understanding of geographic atrophy continues to develop, and recent changes have been made to how this condition is classified, which underscores the importance of accurately monitoring progression. Although no treatment has been approved to manage late-stage dry AMD, complement inhibition, visual cycle modulation, neuroprotection, and stem cell therapy have had encouraging results in clinical trials
Purpose: To systematically review anatomical and functional outcomes subsequent to switching from bevacizumab/ranibizumab to aflibercept monotherapy in patients with treatment-resistant neovascular age-related macular degeneration (nAMD).
The Scientific Committee invites you to participate actively in this congress which will be an extraordinary occasion for the exchange of thoughts and experiences. We look forward to receiving abstracts for consideration and inclusion in the program as oral or poster presentations
The International Committee of Medical Journal Editors has updated the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. The updated Recommendations may be found and downloaded at www.icmje.org. To assist in identifying where changes have been made, an annotated copy of the Recommendations is available at our website under “News & Editorials.”
Anat Loewenstein, MD: Hello, my name is Anat Loewenstein from the Tel Aviv Medical Centre, and the Tel Aviv University in Tel Aviv, Israel. Welcome to this PeerVoice activity on neovascular age-related macular degeneration
At a Glance
Taking an idea and turning it into reality can be an incredibly long and arduous journey
There are a number of pitfalls you need to avoid – IP, finance and competitors
John Marshall has invented and pioneered many technologies in eyecare and beyond – he’s far more than the inventor of the excimer laser
Here, he shares his insights and his stories of innovation
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.